Hormonal
Insulin resistance (IR) fundamentally alters the association between specific lipid subclasses and clinical health markers, causing lipid profiles to diverge significantly from those seen in insulin-sensitive (IS) individuals.
If you have insulin resistance, standard lipid markers (like LDL/HDL ratios) may not predict your health risks the same way they do for healthy people. Your lipid profile's relationship with inflammation and blood sugar changes. Relying solely on standard lipid panels without assessing insulin sensitivity (e.g., fasting insulin, HOMA-IR, or SSPG) may miss critical metabolic risks.
Intriguingly, we found many significant differences in both the effect sizes and the direction of the correlation of lipid signatures and clinical measures between participants with IR and those with IS.
Why this rating
Longitudinal study of 112 participants with dense sampling and rigorous statistical controls (age, sex, BMI).
Source
Dynamic lipidome alterations associated with human health, disease and ageing
Daniel Hornburg et al. · Nature Metabolism · 2023
DOI 10.1038/s42255-023-00880-1
More from this paper
- During acute respiratory viral infections (RVIs), specific lipid subclasses (small TAGs, LPCs, ether-linked PEs) undergo dynamic, phase-dependent changes that correlate with immune response and energy metabolism shifts.Good
- Ether-linked phosphatidylethanolamines (specifically PE-P and PE-O) are associated with lower insulin resistance (SSPG) and healthier metabolic profiles, contrasting with other lipid classes like Ceramides and TAGs which increase with IR.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →